PMID- 8503418
OWN - NLM
STAT- MEDLINE
DCOM- 19930629
LR  - 20190815
IS  - 0272-6386 (Print)
IS  - 0272-6386 (Linking)
VI  - 21
IP  - 6
DP  - 1993 Jun
TI  - Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant 
      human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
PG  - 635-42
AB  - The pharmacokinetics of recombinant human erythropoietin (Epo) were compared 
      after mean single 99.1 U/kg intraperitoneal (IP), intravenous (i.v.), and 
      subcutaneous (SC) doses in eight noninfected patients on peritoneal dialysis in a 
      randomized, three-way, cross-over fashion. Continuous ambulatory peritoneal 
      dialysis was performed in all patients on the days of the study. The IP dose was 
      instilled into an empty peritoneum; total dwell time was 10 hours (4 hours dry, 6 
      hours with 2 L of peritoneal dialysis fluid). Blood samples were collected for 96 
      hours following IP and SC Epo, and for 72 hours following i.v. Epo. For the IP 
      dose, a 10-hour effluent dialysate sample was collected to determine Epo 
      recovery. Enzyme immunoassay was used for Epo analysis. The mean apparent volume 
      of distribution was 0.05 L/kg, equivalent to 4.5% of total body weight; the mean 
      total body clearance was 0.08 mL/min/kg. All eight patients exhibited 
      multiexponential decay in serum Epo concentrations following i.v. Epo. Absorption 
      of IP Epo was significantly greater than previous reports, presumably due to its 
      administration into a dry peritoneum. The maximum concentrations following the IP 
      and SC doses were nearly identical, but amounted to only 5% of the maximum 
      concentrations for the i.v. dose. Subcutaneous Epo took nearly twice as long as 
      IP Epo to achieve peak serum concentrations (17.1 +/- 5.0 hours v 9.4 +/- 1.9 
      hours). Compared with the IP route, the SC dose achieved a higher area under the 
      serum concentration time curve from time 0 to 96 hours (AUC0-96; P = 
      0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Ateshkadi, A
AU  - Ateshkadi A
AD  - School of Pharmacy, University of Wisconsin Hospital and Clinics, Madison 
      53792-1530.
FAU - Johnson, C A
AU  - Johnson CA
FAU - Oxton, L L
AU  - Oxton LL
FAU - Hammond, T G
AU  - Hammond TG
FAU - Bohenek, W S
AU  - Bohenek WS
FAU - Zimmerman, S W
AU  - Zimmerman SW
LA  - eng
GR  - M01 RR03186/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney 
      Foundation
JID - 8110075
RN  - 0 (Recombinant Proteins)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Absorption
MH  - Adult
MH  - Aged
MH  - Biological Availability
MH  - Erythropoietin/administration & dosage/*pharmacokinetics
MH  - Female
MH  - Humans
MH  - Injections, Intraperitoneal
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - *Peritoneal Dialysis, Continuous Ambulatory
MH  - Recombinant Proteins
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - S0272638693001118 [pii]
AID - 10.1016/s0272-6386(12)80037-0 [doi]
PST - ppublish
SO  - Am J Kidney Dis. 1993 Jun;21(6):635-42. doi: 10.1016/s0272-6386(12)80037-0.